Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Autism Spectrum Disorders

Published: Nov 12, 2012

BURLINGTON, Mass., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of an Investigator-Initiated Study (IIS) evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of autism spectrum disorders (ASD). The study is being conducted by the Montefiore Medical Center, Albert Einstein College of Medicine. Dr. Eric Hollander, Clinical Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and the Albert Einstein College of Medicine, is the Principal Investigator of the trial.

Back to news